The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I trial of in situ vaccination with autologous CCL21-modified dendritic cells (CCL21-DC) combined with pembrolizumab for advanced NSCLC.
 
Aaron Elliott Lisberg
Employment - Boston Scientific (I)
Stock and Other Ownership Interests - Boston Scientific (I)
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Jazz Pharmaceuticals; Leica Biosystems; Novocure; Pfizer
Research Funding - AstraZeneca; Calithera Biosciences; Daiichi Sankyo; Dracen; WindMIL
 
Bin Liu
No Relationships to Disclose
 
Ramin Salehi-Rad
No Relationships to Disclose
 
Jay M. Lee
Stock and Other Ownership Interests - Moderna Therapeutics
Consulting or Advisory Role - AstraZeneca; Bristol Myers Squibb Foundation; Genentech/Roche; Novartis
Research Funding - Merck
Travel, Accommodations, Expenses - Genentech/Roche; Genentech/Roche
(OPTIONAL) Uncompensated Relationships - Genentech/Roche; Novartis
 
Linh Tran
No Relationships to Disclose
 
Kostyantyn Krysan
No Relationships to Disclose
 
Raymond Lim
No Relationships to Disclose
 
Camelia Dumitras
No Relationships to Disclose
 
Zhe Jiang
No Relationships to Disclose
 
Fereidoun Abtin
No Relationships to Disclose
 
Robert Suh
No Relationships to Disclose
 
Scott Genshaft
No Relationships to Disclose
 
Gregory Fishbein
No Relationships to Disclose
 
Anita Kaul
No Relationships to Disclose
 
Kanwarpal Kahlon
No Relationships to Disclose
 
Shay Ashouri
No Relationships to Disclose
 
Jonathan Wade Goldman
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech/Roche; Lilly; Trovagene; Vortex Biosciences
Speakers' Bureau - Merck
Research Funding - Abbvie (Inst); Advaxis (Inst); Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Genentech/Roche (Inst); Lilly (Inst); Spectrum Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
David Elashoff
No Relationships to Disclose
 
Edward B. Garon
Consulting or Advisory Role - ABL Bio; Boehringer Ingelheim; Bristol-Myers Squibb; Dracen; Eisai; EMD Serono; GlaxoSmithKline; Merck; Novartis; Sanofi; Shionogi; Xilio Therapeutics
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dynavax Technologies (Inst); EMD Serono (Inst); Genentech (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Neon Therapeutics (Inst); Novartis (Inst)
 
Steven M. Dubinett
Consulting or Advisory Role - Johnson & Johnson
Research Funding - Janssen; Novartis
Patents, Royalties, Other Intellectual Property - IP Related to CCL21 in Cancer Therapy